Charles A. Deignan
2020
In 2020, Charles A. Deignan earned a total compensation of $641.6K as Chief Financial Officer at Clearside Biomedical.
Compensation breakdown
| Non-Equity Incentive Plan | $78,004 |
|---|---|
| Option Awards | $152,010 |
| Salary | $342,876 |
| Stock Awards | $59,250 |
| Other | $9,450 |
| Total | $641,590 |
Deignan received $342.9K in salary, accounting for 53% of the total pay in 2020.
Deignan also received $78K in non-equity incentive plan, $152K in option awards, $59.3K in stock awards and $9.5K in other compensation.
Rankings
In 2020, Charles A. Deignan's compensation ranked 10,274th out of 13,090 executives tracked by ExecPay. In other words, Deignan earned more than 21.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,274 out of 13,090 | 22nd |
Division Manufacturing | 4,403 out of 5,621 | 22nd |
Major group Chemicals And Allied Products | 1,819 out of 2,254 | 19th |
Industry group Drugs | 1,591 out of 1,954 | 19th |
Industry Pharmaceutical Preparations | 1,175 out of 1,459 | 20th |
Source: SEC filing on April 29, 2022.
Deignan's colleagues
We found two more compensation records of executives who worked with Charles A. Deignan at Clearside Biomedical in 2020.
News
Clearside Biomedical CEO George Lasezkay's 2023 pay stays at $1.5M
April 26, 2024
Clearside Biomedical CEO George Lasezkay's 2022 pay falls 35% to $1.5M
April 28, 2023
Clearside Biomedical President and Chief Executive Office George Lasezkay's 2021 pay jumps 71% to $2.3M
April 29, 2022
Clearside Biomedical Chief Commercial Officer Brion Raymond receives $954K in 2018
April 26, 2019